title: New Vaccines against Epidemic Infectious Diseases.
authors.affiliation: From the Coalition for Epidemic Preparedness Innovations (CEPI), the Norwegian Institute of Public Health, and the University of Oslo - all in Oslo (J.-A.R., D.G.); the Harvard T.H. Chan School of Public Health, Boston (J.-A.R.); Chatham House (J.-A.R.), GlaxoSmithKline (A.W.), and the London School of Hygiene and Tropical Medicine (P.P.) - all in London; the International AIDS Vaccine Initiative (M.F.) and Johnson & Johnson (P.S.) - both in New York; the University of Pennsylvania, Philadelphia (S.P.); the Department of Biotechnology, Ministry of Science and Technology, New Delhi, India (K.V.R.); and the Directorate General for Research and Innovation, European Commission, Brussels (R.D.-A.).
authors.forename: John-Arne
authors.initials: JA
authors.lastname: Røttingen
authors.affiliation: From the Coalition for Epidemic Preparedness Innovations (CEPI), the Norwegian Institute of Public Health, and the University of Oslo - all in Oslo (J.-A.R., D.G.); the Harvard T.H. Chan School of Public Health, Boston (J.-A.R.); Chatham House (J.-A.R.), GlaxoSmithKline (A.W.), and the London School of Hygiene and Tropical Medicine (P.P.) - all in London; the International AIDS Vaccine Initiative (M.F.) and Johnson & Johnson (P.S.) - both in New York; the University of Pennsylvania, Philadelphia (S.P.); the Department of Biotechnology, Ministry of Science and Technology, New Delhi, India (K.V.R.); and the Directorate General for Research and Innovation, European Commission, Brussels (R.D.-A.).
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Gouglas
authors.affiliation: From the Coalition for Epidemic Preparedness Innovations (CEPI), the Norwegian Institute of Public Health, and the University of Oslo - all in Oslo (J.-A.R., D.G.); the Harvard T.H. Chan School of Public Health, Boston (J.-A.R.); Chatham House (J.-A.R.), GlaxoSmithKline (A.W.), and the London School of Hygiene and Tropical Medicine (P.P.) - all in London; the International AIDS Vaccine Initiative (M.F.) and Johnson & Johnson (P.S.) - both in New York; the University of Pennsylvania, Philadelphia (S.P.); the Department of Biotechnology, Ministry of Science and Technology, New Delhi, India (K.V.R.); and the Directorate General for Research and Innovation, European Commission, Brussels (R.D.-A.).
authors.forename: Mark
authors.initials: M
authors.lastname: Feinberg
authors.affiliation: From the Coalition for Epidemic Preparedness Innovations (CEPI), the Norwegian Institute of Public Health, and the University of Oslo - all in Oslo (J.-A.R., D.G.); the Harvard T.H. Chan School of Public Health, Boston (J.-A.R.); Chatham House (J.-A.R.), GlaxoSmithKline (A.W.), and the London School of Hygiene and Tropical Medicine (P.P.) - all in London; the International AIDS Vaccine Initiative (M.F.) and Johnson & Johnson (P.S.) - both in New York; the University of Pennsylvania, Philadelphia (S.P.); the Department of Biotechnology, Ministry of Science and Technology, New Delhi, India (K.V.R.); and the Directorate General for Research and Innovation, European Commission, Brussels (R.D.-A.).
authors.forename: Stanley
authors.initials: S
authors.lastname: Plotkin
authors.affiliation: From the Coalition for Epidemic Preparedness Innovations (CEPI), the Norwegian Institute of Public Health, and the University of Oslo - all in Oslo (J.-A.R., D.G.); the Harvard T.H. Chan School of Public Health, Boston (J.-A.R.); Chatham House (J.-A.R.), GlaxoSmithKline (A.W.), and the London School of Hygiene and Tropical Medicine (P.P.) - all in London; the International AIDS Vaccine Initiative (M.F.) and Johnson & Johnson (P.S.) - both in New York; the University of Pennsylvania, Philadelphia (S.P.); the Department of Biotechnology, Ministry of Science and Technology, New Delhi, India (K.V.R.); and the Directorate General for Research and Innovation, European Commission, Brussels (R.D.-A.).
authors.forename: Krishnaswamy V
authors.initials: KV
authors.lastname: Raghavan
authors.affiliation: From the Coalition for Epidemic Preparedness Innovations (CEPI), the Norwegian Institute of Public Health, and the University of Oslo - all in Oslo (J.-A.R., D.G.); the Harvard T.H. Chan School of Public Health, Boston (J.-A.R.); Chatham House (J.-A.R.), GlaxoSmithKline (A.W.), and the London School of Hygiene and Tropical Medicine (P.P.) - all in London; the International AIDS Vaccine Initiative (M.F.) and Johnson & Johnson (P.S.) - both in New York; the University of Pennsylvania, Philadelphia (S.P.); the Department of Biotechnology, Ministry of Science and Technology, New Delhi, India (K.V.R.); and the Directorate General for Research and Innovation, European Commission, Brussels (R.D.-A.).
authors.forename: Andrew
authors.initials: A
authors.lastname: Witty
authors.affiliation: From the Coalition for Epidemic Preparedness Innovations (CEPI), the Norwegian Institute of Public Health, and the University of Oslo - all in Oslo (J.-A.R., D.G.); the Harvard T.H. Chan School of Public Health, Boston (J.-A.R.); Chatham House (J.-A.R.), GlaxoSmithKline (A.W.), and the London School of Hygiene and Tropical Medicine (P.P.) - all in London; the International AIDS Vaccine Initiative (M.F.) and Johnson & Johnson (P.S.) - both in New York; the University of Pennsylvania, Philadelphia (S.P.); the Department of Biotechnology, Ministry of Science and Technology, New Delhi, India (K.V.R.); and the Directorate General for Research and Innovation, European Commission, Brussels (R.D.-A.).
authors.forename: Ruxandra
authors.initials: R
authors.lastname: Draghia-Akli
authors.affiliation: From the Coalition for Epidemic Preparedness Innovations (CEPI), the Norwegian Institute of Public Health, and the University of Oslo - all in Oslo (J.-A.R., D.G.); the Harvard T.H. Chan School of Public Health, Boston (J.-A.R.); Chatham House (J.-A.R.), GlaxoSmithKline (A.W.), and the London School of Hygiene and Tropical Medicine (P.P.) - all in London; the International AIDS Vaccine Initiative (M.F.) and Johnson & Johnson (P.S.) - both in New York; the University of Pennsylvania, Philadelphia (S.P.); the Department of Biotechnology, Ministry of Science and Technology, New Delhi, India (K.V.R.); and the Directorate General for Research and Innovation, European Commission, Brussels (R.D.-A.).
authors.forename: Paul
authors.initials: P
authors.lastname: Stoffels
authors.affiliation: From the Coalition for Epidemic Preparedness Innovations (CEPI), the Norwegian Institute of Public Health, and the University of Oslo - all in Oslo (J.-A.R., D.G.); the Harvard T.H. Chan School of Public Health, Boston (J.-A.R.); Chatham House (J.-A.R.), GlaxoSmithKline (A.W.), and the London School of Hygiene and Tropical Medicine (P.P.) - all in London; the International AIDS Vaccine Initiative (M.F.) and Johnson & Johnson (P.S.) - both in New York; the University of Pennsylvania, Philadelphia (S.P.); the Department of Biotechnology, Ministry of Science and Technology, New Delhi, India (K.V.R.); and the Directorate General for Research and Innovation, European Commission, Brussels (R.D.-A.).
authors.forename: Peter
authors.initials: P
authors.lastname: Piot
mesh_terms: D003140:Communicable Disease Control; D021821:Communicable Diseases, Emerging / Q000453:epidemiology / Q000517:prevention & control*; D055808:Drug Discovery; D058872:Epidemics / Q000517:prevention & control*; D006801:Humans; D014612:Vaccines
chemical_list: D014612:Vaccines